You can now read 5 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

FDA to review AVEO cancer drug

AVEO Oncology, a Cambridge-based cancer therapeutics company, and its Japanese partner, Astellas Pharma Inc., said Wednesday that federal regulators have agreed to review their drug candidate for kidney cancer.

In a press release, the companies said the Food and Drug Administration has accepted their new drug application for tivozanib, a treatment for patients with advanced renal cell carcinoma, or kidney cancer. Tivozanib is an investigational medicine and is not currently approved in any country. If it gets regulatory approval, AVEO said the proposed brand name for the drug is Tivopath.

Continue reading below

According to the timelines established by the Prescription Drug User Fee Act, the review of tivozanib’s new drug application is expected to be complete by July 28, AVEO and Astellas said. The FDA’s acceptance of the application triggers a $15 million milestone payment to AVEO under its development and commercialization agreement with Astellas.

Chris Reidy can be reached at reidy@globe.com.
Loading comments...
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com
Already a subscriber?
Your city. Your stories. Your Globe.
Yours FREE for two weeks.
Enjoy free unlimited access to Globe.com for the next two weeks.
Limited time only - No credit card required!
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.
Thanks & Welcome to Globe.com
You now have unlimited access for the next two weeks.
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.